Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 1 3 Hamid Attarian Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran H Rezvani Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran M GHadyani Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran S Attarian Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran A Okhovatian Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran A Khosravi Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. Patient and Method: 32 eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with Carboplatin (AUC= 6) and Paclitaxel (175 mg/m3) every 4 weeks for 6 cycles, or, until disease progression or severe toxicity. Result: The ORR was 54% (16 out of 30), CR in 4 and PR in 12. The median progression free survival was 8.2 months. The 6 months overall survival was seen in 80% of trhe patients. The toxicity was generally tolerable. Conclusion: The combination of Carboplatin plus Paclitaxel was well tolerated in this trial. This regimen demonstrated feasible success in curing advanced endometrial cancer compared to other combination therapies used before (in terms of RR and toxicity). https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/215 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/215/208

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 4 7 Ardeshir Ghavamzadeh Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Abolghasem Allahyari Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran M Esfandbod Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran M Malekpour Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Akram Karimi Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Arpi Manokian Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran M Asadian Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Farnaz Khatami Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Autologous stem cells have greatly influenced the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias. This is a preliminary study comparing the time of engraftment, mortality rate and cost of treatment in outpatient versus inpatient autologous stem cell transplantation (SCT) in Iran. Patients and Methods: 11 outpatients (6 Hodgkin Lymphoma (HL), 3 Non-Hodgkin Lymphoma (NHL) and 2 Acute Myeloid Leukemia (AML)) were compared with 32 inpatients (15 HL, 8 NHL and 9 AML) from May, 2008 to December, 2008. All patients were in complete remission and without significant organ failure. They received conditioning regimen (CEAM for NHL and HL, Busulfan and Etoposide for AML) and stem cell infusion in hospital. The day after SCT, the outpatient group was discharged and followed up by an outpatient SCT team to be re-hospitalized, if indicated. Results: For outpatients and inpatients, the median period to WBC engraftment was 11 and 12 days (p-value=0.03), the timeframe to PLT engraftment was 15 and 25 days (p-value=0.20) and the number of transfused single-donor PLT was 3 and 4.5 units (p-value=0.21). The duration of neutropenic fever was 6 and 9 days (p-value=0.001), the duration of hospitalization after SCT was 0 and 16 (p-value<0.001), respectively. All outpatients are alive but three inpatients died between days +35 and +100 following SCT due to transplantation complications. The cost of the drugs used for treatment of neutropenic fever was 6 times higher in the inpatient group. Conclusion: The outpatient autologous SCT in malignant hematological disorders is feasible and comparable to inpatient protocols in Iran. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/216 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/216/209

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 8 13 Gholamreza Bahoush Pediatric Hematology-Oncology Department, Ali-Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran Mardavizh Albouyeh Pediatric Hematology-Oncology Department, Shohada General Hospital, Shahid-Beheshti University of Medical Sciences, Tehran, Iran Parvaneh Vossough 1Pediatric Hematology-Oncology Department, Ali-Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Imatinib Mesylate is a selective inhibitor of TK and is considered now to be the frontline therapeutic agent during the chronic phase of CML. We have evaluated the efficacy of it on children with chronic-phase of CML. Patients and Methods: In a clinical trial study over the past 3 years, 14 patients (8 females and 6 males, 2.5-14 years old) were admitted with a diagnosis of CML. Seven patients who were in the early chronic-phase and seven who were in the late chronic-phase suffered from hematological relapse while being treated with conventional therapy. All of them had positive BCR-ABL in peripheral blood and bone marrow. Glivec was given as an oral dose of 300mg/m2/d. Then, regular monitoring was done for hematological and cytogenetic response, toxic effects, disease progression and survival. Results: All seven patients with newly- diagnosed CML and five previously treated patients attained complete and sustained hematological and cytogenetic remission in a follow-up period over 2 to 30 months (the mean was 22.5). One patient was taken off study because of drug intolerance. One patient in each group relapsed after initial response and died from progressive disease. Overall survival was 86%. No major side effects were noted and there was no drug- related mortality. Conclusion: Glivec has proved to be effective in inducing prolonged complete hematological and cytogenetic remission in newly- diagnosed as well as previously treated children with CML. One major problem is prolonged, unlimited and continued therapy which results in poor compliance as time goes by. In addition, in developing countries, high cost and suboptimal accessibility would make its routine use quite difficult. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/217 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/217/210

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 14 16 M Hadjibabaie Clinical Pharmacology Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Masoud Iravani Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Ahmad Reza Shamshiri Epidemiology and Biostatistics Department, Faculty of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran Z Zaker Clinical Pharmacology Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran A Mousavi Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran E Kalantar Immunology Department, Iran University of Medical Sciences, Tehran, Iran M Mojtahedzadeh Clinical Pharmacology Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Zinc (Zn) deficiency can cause significant defects in cellular immunity. Hematopoietic stem cell transplantation (HSCT) patients usually experience serious deficiencies of all components of the immune system. Therefore, the maintenance of a normal Zn status may be important in this group of patients. Patients and Methods: Serum Zn levels were analyzed in 55 patients during the HSCT period. As Zn-related factors, serum copper (Cu) levels and alkaline phosphatase (ALP) activity were also measured. Results: There was decrease in Zn values immediate post-transplant period (at day +10) when compared to pre-HSCT levels (P=0.06). In patients who developed hypozincemia, adverse events appeared to occur more frequently. Conclusion: This study suggests that maintaining a normal Zn status can be important in HSCT patients and Zn deficiency may be a risk factor causing adverse effects. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/218 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/218/211

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 17 20 Amir Ali Hamidieh Pediatric Hematology- Oncology and Stem Cell Transplantation Department, Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran B Moradbeag Faculty of Medicine, Qom Islamic Azad University, Qom, Iran F Pasha Faculty of Medicine, Tehran Islamic Azad University, Tehran, Iran Mehdi Jalili Pediatric Hematology- Oncology and Stem Cell Transplantation Department, ematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran M Hadjibabaie Clinical Pharmacology Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran M Keshavarznia Faculty of Medicine, Qom Islamic Azad University, Qom, Iran 2015 10 01 Introduction: Hypoparathyroidism (HPT) is an irreversible but preventable disorder caused by an iron overload which can be considered a typical complication in patients with beta-thalassemia major. Patients and method: Parathyroid function was evaluated in 130 patients in Qom, Iran, who suffered from beta-thalassemia major. Their serum ferritin levels were checked for monitoring of chelation therapy effects. Results: The prevalence of HPT was 14.6% (19/130). The median age of patients with HPT was significantly higher than of patients without HPT (18 vs. 15 years; P=0.03). Serum ferritin levels was not significantly different between the two groups (median: 2709 vs. 1512; P=0.95). The prevalence of cardiac diastolic dysfunction in patients with HPT was significantly higher than in normal thalassemic patients (3.1% vs. 15.8%, P=0.04). Patients with hypoparathyroidism demonstrated abnormal glucose metabolism (0% vs. 15.8%; P=0.003). Conclusion: the high prevalence of hypoparathyroidism demonstrated poor chelation therapy in these patients. Close monitoring of ferritin level was recommended. Also, the measurement of parathyroid hormone on a regular basis for all thalassemic patients was recommended. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/219 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/219/212

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 21 28 Somayeh Shahrokhi Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran MH Zuhair Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran MA Mohagheghi Cancer Research Center, Cancer Institute, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran T Ghazanfari Department of Immunology, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran M Ebtekar Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran 2015 10 01 Introduction: Shark cartilage has been shown to have some inhibitory effects on angiogenesis, metastasis, cell adhesion and proteolysis. Patients and Methods: In this study, we evaluated the effect of shark cartilage on immune response in three treatment session of 3 weeks, 6 weeks and 12 weeks on stage III invasive ductal carcinoma patients (n=15) compared to patients treated with a starch placebo (n=15). Results: The results indicated a significant increase after an initial 3 weeks treatment period in the level of IFNγ, but no significant decrease in the level of IL-4 before and after the treatment with shark cartilage. After 6 weeks, we noticed a significant increase (P<0.05) in the level of IFNγ, but no significant increase in the level of IL-4 was observed after the treatment with shark cartilage. After 12 weeks, a significant increase in the level of IFNγ and a significant decrease in the level of IL-4 after the treatment with shark cartilage was observed; while there was no significant difference in the levels of both IFNγ and IL-4 at 3, 6 and 12 weeks treatment in the placebo group. We also evaluated the lymphocytes proliferation in pre and post treatments with shark cartilage or a placebo. Our findings showed a significant increase in lymphocyte proliferation in the three-week treatment. Conclusion: It is concluded that shark cartilage can stimulate immune response in a short period of time after treatment with it and modulate immune response in longer treatment duration toward Th1 cytokine pattern. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/220 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/220/213 International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 30 33 Mitra Kazemi Jahromi Hematology-Oncology Department, Rasul-e Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran Ali Shahriari Ahmadi Hematology-Oncology Department, Rasul-e Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran Kaveh Mousavi kani Hematology-Oncology Department, Rasul-e Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Cardiac dysfunctions have been well known in patients with Major thalassemia. Some studies have focused on differences in blood pressure and heart rate between these patients and normal population, while this view has not been proven in other studies. Given the importance of hemodynamic factors in the health of these individuals, we intend to test the hypothesis as to whether or not hemodynamic factors of these patients differ from normal subjects. Methods: Patients were selected from among the thalassemic patients referred to a blood clinic of one of the third-level hospitals in Tehran. Finally, 50 patients and 50 normal subjects were studied in two groups. All subjects have been assessed using Holter monitoring. Mean average systolic blood pressure and heart rate of subjects were recorded for a period of 24 hours. In addition, demographic data on the subjects, and some laboratory tests (such as serum lipid profile and glucose levels of the patients) were also determined and compared between the two groups. Results: 100 people were evaluated in two groups, including 50 patients with thalassemia major and 50 normal subjects, matched by age and gender. The mean age of the subjects was 16.3 ± 6.7 years; and there is no significant difference in mean age of both groups.23 female patients (46%) were in the case group, and 21 female patients (42%) were in the healthy group, the ratio for which there is no statistically significant difference between the two groups (P> 0. 05). The average level of serum glucose, lipid profiles, as well as none of the hemodynamic factors had no statistically significant difference in the two groups.Only the mean systolic blood pressure was significantly lower in male patients than among men without the disease. Discussion: Despite the lack of difference in blood pressure between the case group and others, it seems that gender could plays a protective role against cardiovascular diseases in men with thalassemia major. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/269 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/269/262

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 1 2011 03 15 34 38 Mehrdad Payandeh Hematology-oncology department, Taleghany Hospital, Kermanshah University of medical science (KUMS), Kermanshah, Iran Mehrnoush Aeinfar Hematology-oncology department, Taleghany Hospital, Kermanshah University of medical science (KUMS),Kermanshah, Iran Mohammad Erfan Zare Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Hooshang Yusefi Blood Transfusion Center, Kermanshah, Iran Ebrahim Soltanian Blood Transfusion Center, Kermanshah, Iran 2015 10 01 The case of a 52 old women with Hodgkin’s disease of 15 years duration is described. During 4 months ago when she be in the remission phase during every 6 months her follow up she complaint with paranoid minds, urinary incontinency, headache, dizziness and blurred vision started. Papilledema and left hemiparesia were detected. Brain MRI pointed to intracranial invasion by the disease. Therapeutic test with steroids brought to amelioration; therefore, subsequent skull irradiation and chemotherapy were given which improved her condition markedly. For the diagnosis we need newer diag